Laura Genn

Taking daily anticholinergic drugs when 55 or older increases the risk of dementia, according to this nested case-control study.

When onset occurs before the age of 18, multiple sclerosis causes more severe cognitive impairment than in equivalent adult-onset cases.

The FDA had previously only certified Symdeko tablets for treatment of children aged 12 years and older.

A new study reframes rheumatoid arthritis, broadly considered to be a connective tissue disorder, as having deeper neurological ties.

A pair of phase 3 studies showed 20% symptomatic improvement in patients with psoriatic arthritis who were treated with guselkumab.

The lead investigator of a new meta-analysis shared the critical need for further studies on psychotherapeutic versus pharmacological treatments for PTSD.

A new meta-analysis showed that while psychotherapeutic treatments are generally preferred, there’s a dearth of data with which to defend that decision.

Even when comorbidities or poor prognosis are considered, osteoporosis specifically, severely raises the risk of hip fracture for women aged 80 or older.

A trio of phase 3 psoriatic arthritis trials showed that 30 mg of apremilast, twice daily, increased the likelihood of achieving low disease activity or remission.

A new study of long-term data demonstrates that infliximab and golimumab are both effective, safe treatments for symptoms of ankylosing spondylitis.

The new study indicated that administration of a bisphosphonate before denosumab treatment, rather than at discontinuation, was far more effective at preventing rebound.

Assorted trials and a long-term exposure study of 3770 patients with rheumatoid arthritis further demonstrate baricitinib’s previously recorded safety profile.

A FUTURE 5 trial and MAXIMIZE trial demonstrate that Cosentyx frequently stops radiographic progression and lessens axial manifestations, respectively.

The ACP's guideline committee chair discusses the thought process that went into their own update on clinical standards of guidance.

Less than half of US adults with either HBV or HCV infection are aware of their condition, and even among those aware, few receive appropriate treatment.

Kaiser Permanente Northern California’s study shows that the pertussis vaccine weakens as time passes after a patient's most recent vaccination.

Experimental drug lemborexant underwent several phase 3 studies presented at the annual SLEEP 2019 meeting.

The American College of Physicians (ACP) released a paper detailing their methods for creating clinical guidelines and guidance statements.

Patients who self-referred themselves to a hospital for suicidal and/or self-harming actions did not improve more than patients who received standard treatment apart from hospitalization.

A new study debunks preceding fears that direct-acting antivirals increase the likelihood of adverse events for patients with the hepatitis C virus.

Ruben Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses treating myelofibrosis with ruxolitinib therapy.

Ruben Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses the visible symptoms and diagnosis process for patients with myelofibrosis.

A new study shows that loss of phosphodiesterase, not just dopamine, indicates a worsening of motor symptoms in patients with Parkinson disease.

Patients who received the implant in addition to the surgery showed more positive results than the control group in a randomized, single-masked study.

The new occluder, which can repair both small and large cardiovascular defects, received premarket approval.

A new study found that elements such as birth order, low parental education, or low birthweight could increase suicide risk throughout a person’s lifespan.

Hu5F9-G4, aided by azacytidine, showed the potential to remove signals on cancer cells that would normally prevent a patient’s body from eliminating said cells.

New analysis shows patients from either of these populations often take longer to be diagnosed with leukemia or lymphoma than their male or median-income counterparts.

A new study shows a profound lack of genetic markers, allowing doctors to standardize treatment.

A new study shows that adding this pair of drugs reduces costs and side effects while increasing efficacy.